
Thyrocare (THYROCARE) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.9B
Gross Profit
1.4B
71.18%
Operating Income
463.6M
24.02%
Net Income
382.9M
19.84%
EPS (Diluted)
₹7.33
Balance Sheet Metrics
Total Assets
6.9B
Total Liabilities
1.5B
Shareholders Equity
5.5B
Debt to Equity
0.27
Cash Flow Metrics
Operating Cash Flow
517.5M
Free Cash Flow
94.2M
Revenue & Profitability Trend
Thyrocare Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 6.9B | 5.7B | 5.3B | 5.9B | 4.9B |
Cost of Goods Sold | 1.9B | 1.7B | 1.6B | 1.7B | 1.6B |
Gross Profit | 5.0B | 4.1B | 3.6B | 4.2B | 3.3B |
Gross Margin % | 72.2% | 70.9% | 69.0% | 71.2% | 66.9% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 774.2M | 656.7M | 435.3M | 395.0M | 372.4M |
Other Operating Expenses | 991.4M | 877.8M | 848.2M | 798.1M | 631.6M |
Total Operating Expenses | 1.8B | 1.5B | 1.3B | 1.2B | 1.0B |
Operating Income | 1.4B | 927.1M | 846.2M | 2.0B | 1.4B |
Operating Margin % | 19.8% | 16.2% | 16.1% | 34.3% | 28.5% |
Non-Operating Items | |||||
Interest Income | 51.0M | 27.1M | 13.8M | 7.1M | 7.9M |
Interest Expense | 30.5M | 42.0M | 23.5M | 23.7M | 8.7M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 1.5B | 959.8M | 885.9M | 2.3B | 1.5B |
Income Tax | 546.9M | 264.9M | 242.3M | 515.8M | 393.2M |
Effective Tax Rate % | 37.6% | 27.6% | 27.4% | 22.7% | 25.8% |
Net Income | 907.5M | 694.9M | 643.6M | 1.8B | 1.1B |
Net Margin % | 13.2% | 12.2% | 12.2% | 29.9% | 22.9% |
Key Metrics | |||||
EBITDA | 1.9B | 1.4B | 1.2B | 2.4B | 1.7B |
EPS (Basic) | ₹17.28 | ₹13.42 | ₹12.16 | ₹33.30 | ₹21.41 |
EPS (Diluted) | ₹17.23 | ₹13.40 | ₹12.14 | ₹33.25 | ₹21.37 |
Basic Shares Outstanding | 52965805 | 52937587 | 52917822 | 52888361 | 52850753 |
Diluted Shares Outstanding | 52965805 | 52937587 | 52917822 | 52888361 | 52850753 |
Income Statement Trend
Thyrocare Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 176.8M | 93.0M | 177.7M | 136.3M | 132.0M |
Short-term Investments | 1.7B | 1.4B | 1.2B | 1.3B | 1.0B |
Accounts Receivable | 730.0M | 434.7M | 851.2M | 932.0M | 446.8M |
Inventory | 465.4M | 475.2M | 276.7M | 245.3M | 233.6M |
Other Current Assets | 4.1M | 75.6M | 53.2M | 112.8M | 28.4M |
Total Current Assets | 3.4B | 2.8B | 2.7B | 2.7B | 2.4B |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.8B | 2.0B | 1.9B | 1.8B | 1.5B |
Goodwill | 2.2B | 2.1B | 2.0B | 2.0B | 2.0B |
Intangible Assets | 48.4M | 6.9M | 7.9M | 8.3M | 9.7M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 100.0K | 100.0K | 50.7M | 34.0M | 100.0K |
Total Non-Current Assets | 3.6B | 3.7B | 3.6B | 3.4B | 3.1B |
Total Assets | 6.9B | 6.4B | 6.3B | 6.1B | 5.5B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 762.1M | 401.1M | 239.9M | 165.3M | 250.1M |
Short-term Debt | 77.6M | 196.3M | 71.9M | 50.0M | 30.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 300.0K | 5.0M | 79.1M | 111.7M | 272.0M |
Total Current Liabilities | 1.2B | 904.8M | 771.0M | 645.2M | 951.0M |
Non-Current Liabilities | |||||
Long-term Debt | 169.2M | 227.1M | 161.2M | 157.0M | 54.5M |
Deferred Tax Liabilities | - | 0 | 9.8M | 6.0M | 43.9M |
Other Non-Current Liabilities | -400.0K | -4.3M | - | - | 43.9M |
Total Non-Current Liabilities | 238.5M | 257.7M | 204.0M | 165.7M | 234.2M |
Total Liabilities | 1.5B | 1.2B | 975.0M | 810.9M | 1.2B |
Equity | |||||
Common Stock | 529.9M | 529.5M | 529.3M | 529.0M | 528.7M |
Retained Earnings | 3.1B | 3.2B | 3.4B | 3.6B | 2.6B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 5.5B | 5.3B | 5.4B | 5.3B | 4.3B |
Key Metrics | |||||
Total Debt | 246.8M | 423.4M | 233.1M | 207.0M | 84.9M |
Working Capital | 2.2B | 1.9B | 2.0B | 2.1B | 1.5B |
Balance Sheet Composition
Thyrocare Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 1.5B | 955.9M | 874.1M | 2.3B | 1.5B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 245.1M | 166.7M | 211.7M | 23.2M | 16.8M |
Working Capital Changes | -248.6M | 155.1M | -20.6M | -607.3M | -267.3M |
Operating Cash Flow | 1.5B | 1.3B | 1.1B | 1.7B | 1.3B |
Investing Activities | |||||
Capital Expenditures | -448.8M | -608.6M | -415.5M | -149.0M | -213.8M |
Acquisitions | -112.5M | -35.2M | 0 | 42.5M | 42.5M |
Investment Purchases | -65.6M | -314.0M | -1.9B | -1.7B | -1.4B |
Investment Sales | 82.0M | - | 1.9B | 1.6B | 1.0B |
Investing Cash Flow | -544.9M | -957.8M | -401.6M | -243.0M | -490.3M |
Financing Activities | |||||
Share Repurchases | - | - | -55.3M | -53.8M | - |
Dividends Paid | -953.1M | -952.7M | -793.5M | -793.1M | -528.4M |
Debt Issuance | 0 | 286.2M | 0 | - | - |
Debt Repayment | -215.9M | -70.3M | 0 | 0 | -25.0M |
Financing Cash Flow | -1.2B | -724.5M | -839.3M | -846.6M | -553.2M |
Free Cash Flow | 1.5B | 1.1B | 856.6M | 755.8M | 880.4M |
Net Change in Cash | -237.5M | -372.4M | -166.0M | 621.9M | 232.4M |
Cash Flow Trend
Thyrocare Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
66.67
Forward P/E
57.40
Price to Book
12.96
Price to Sales
9.80
PEG Ratio
57.40
Profitability Ratios
Profit Margin
14.69%
Operating Margin
24.02%
Return on Equity
16.73%
Return on Assets
13.21%
Financial Health
Current Ratio
2.77
Debt to Equity
4.51
Beta
0.24
Per Share Data
EPS (TTM)
₹20.06
Book Value per Share
₹103.18
Revenue per Share
₹136.92
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
thyrocare | 70.9B | 66.67 | 12.96 | 16.73% | 14.69% | 4.51 |
Dr. Lal PathLabs | 268.6B | 52.27 | 12.35 | 22.08% | 20.29% | 7.14 |
Syngene | 262.6B | 51.97 | 5.56 | 10.50% | 13.61% | 12.23 |
Sai Life Sciences | 171.5B | 95.37 | 8.03 | 7.99% | 12.77% | 16.56 |
Vijaya Diagnostic | 107.1B | 71.11 | 13.43 | 17.90% | 21.04% | 39.99 |
Metropolis | 106.0B | 69.22 | 7.95 | 11.96% | 10.89% | 15.30 |
Financial data is updated regularly. All figures are in the company's reporting currency.